Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$65.43
+3.7%		$53.50
$14.03
▼
$72.51
$3.38B2.38940,106 shs1.50 million shs
Celcuity, Inc. stock logo
CELC
Celcuity
$63.19
-4.0%		$85.58
$45.03
▼
$151.02
$3.09B0.11.10 million shs1.50 million shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$34.26
-5.0%		$38.12
$26.44
▼
$42.68
$3.01B-0.041.03 million shs1.03 million shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$2.41
-8.0%		$3.39
$2.37
▼
$6.55
$721.46M2.183.23 million shs4.90 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
-0.86%-9.63%+25.59%+118.18%+338.64%
Celcuity, Inc. stock logo
CELC
Celcuity
-3.08%-10.55%-21.09%-40.70%+42.93%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-0.14%-5.25%-4.07%-1.61%+37.42%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-6.09%-9.03%-16.29%-26.61%-39.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$65.43
+3.7%		$53.50
$14.03
▼
$72.51
$3.38B2.38940,106 shs1.50 million shs
Celcuity, Inc. stock logo
CELC
Celcuity
$63.19
-4.0%		$85.58
$45.03
▼
$151.02
$3.09B0.11.10 million shs1.50 million shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$34.26
-5.0%		$38.12
$26.44
▼
$42.68
$3.01B-0.041.03 million shs1.03 million shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$2.41
-8.0%		$3.39
$2.37
▼
$6.55
$721.46M2.183.23 million shs4.90 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
-0.86%-9.63%+25.59%+118.18%+338.64%
Celcuity, Inc. stock logo
CELC
Celcuity
-3.08%-10.55%-21.09%-40.70%+42.93%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-0.14%-5.25%-4.07%-1.61%+37.42%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-6.09%-9.03%-16.29%-26.61%-39.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CareDx, Inc. stock logo
CDNA
CareDx
2.38
Hold$54.00-18.87% Downside
Celcuity, Inc. stock logo
CELC
Celcuity
2.83
Moderate Buy$154.25142.08% Upside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.80
Moderate Buy$52.6952.63% Upside
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
2.80
Moderate Buy$9.33288.08% Upside

Current Analyst Ratings Breakdown

Latest SANA, CELC, CDNA, and IDYA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
CareDx, Inc. stock logo
CDNA
CareDx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C) ➝ Hold (C+)
10/2/2026
CareDx, Inc. stock logo
CDNA
CareDx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
9/30/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$140.00 ➝ $134.00
9/24/2026
CareDx, Inc. stock logo
CDNA
CareDx
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$60.00 ➝ $74.00
9/22/2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
9/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight$157.00
9/9/2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$54.00 ➝ $57.00
9/2/2026
CareDx, Inc. stock logo
CDNA
CareDx
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$65.00
9/2/2026
CareDx, Inc. stock logo
CDNA
CareDx
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$65.00
9/1/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/1/2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CareDx, Inc. stock logo
CDNA
CareDx
$379.80M9.07N/AN/A$5.89 per share11.30
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$2.17 per shareN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$218.71M13.87N/AN/A$11.67 per share2.96
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/A$0.60 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CareDx, Inc. stock logo
CDNA
CareDx
-$21.35M$2.0732.13105.65N/A24.23%2.87%2.17%11/3/2026 (Estimated)
Celcuity, Inc. stock logo
CELC
Celcuity
-$177.04M-$4.30N/AN/AN/AN/A-350.78%-41.54%11/11/2026 (Estimated)
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$113.70M-$1.94N/AN/AN/A-75.93%-16.73%-15.34%11/9/2026 (Estimated)
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$244.17M-$0.76N/AN/AN/AN/A-103.02%-39.16%11/5/2026 (Estimated)

Latest SANA, CELC, CDNA, and IDYA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$1.17N/AN/AN/A$6.84 millionN/A
11/5/2026Q3 2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.1478N/AN/AN/AN/AN/A
11/3/2026Q3 2026
CareDx, Inc. stock logo
CDNA
CareDx
$0.2552N/AN/AN/A$121.95 millionN/A
8/13/2026Q2 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.16-$1.44-$0.28-$1.44$4.42 millionN/A
8/10/2026Q2 2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.1469-$0.13+$0.0169-$0.22N/AN/A
8/4/2026Q2 2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$1.06-$1.22-$0.16-$1.22$8.02 million$8.86 million
7/30/2026Q2 2026
CareDx, Inc. stock logo
CDNA
CareDx
$0.2321$0.37+$0.1379$2.07$114.05 million$131.95 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CareDx, Inc. stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CareDx, Inc. stock logo
CDNA
CareDx
N/A
4.58
4.51
Celcuity, Inc. stock logo
CELC
Celcuity
6.04
8.93
8.93
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
10.45
10.45
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/A
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
CareDx, Inc. stock logo
CDNA
CareDx
N/A
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
98.29%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
88.23%

Insider Ownership

CompanyInsider Ownership
CareDx, Inc. stock logo
CDNA
CareDx
2.40%
Celcuity, Inc. stock logo
CELC
Celcuity
13.33%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4.70%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
25.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
CareDx, Inc. stock logo
CDNA
CareDx
76551.73 million50.49 millionOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
15548.93 million42.41 millionOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
14587.86 million83.73 millionOptionable
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
142299.36 million223.32 millionOptionable

Recent News About These Companies

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.7% - What's Next?
October 13 at 1:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-stock-price-down-67-whats-next-2026-10-13/
Sana Biotechnology: A Shot At Diabetes
October 13 at 7:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4953698-sana-biotechnology-a-shot-at-diabetes
Sana Biotechnology (NASDAQ:SANA) Hits New 52-Week Low - Should You Sell?
October 12 at 3:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-hits-new-52-week-low-should-you-sell-2026-10-12/
Sana Biotechnology, Inc. (SANA) - What Are Analysts Thinking About This Stock?
October 10 at 4:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-sana-biotechnology-inc-sana-what-are-analysts-thinking-about-this-stock-2026-10-10/
Sana Biotechnology, Inc. Common Stock
October 9, 2026  |  fxempire.comF
Sana Biotechnology (NASDAQ:SANA) Shares Up 3.1% - Here's Why
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-shares-up-31-heres-why-2026-10-07/
Bank of America Corp DE Purchases New Holdings in Sana Biotechnology, Inc. $SANA
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-purchases-new-holdings-in-sana-biotechnology-inc-sana-2026-09-25/
6 'moonshot' biotech stocks that offer big risks, bigger rewards
September 23, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/6-moonshot-biotech-stocks-that-offer-big-risks-bigger-rewards/ar-AA2cNIJ1
Sana Biotechnology (NASDAQ:SANA) Shares Down 7.2% - Should You Sell?
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-shares-down-72-should-you-sell-2026-09-23/
Sana Biotechnology (SANA)
September 23, 2026  |  es.investing.comhttps://es.investing.com/equities/sana-biotechnology
Sana Biotechnology (NASDAQ:SANA) Shares Up 10.4% - Still a Buy?
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-shares-up-104-still-a-buy-2026-09-17/
Sana Biotechnology, Inc. (SANA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949033-sana-biotechnology-inc-sana-presents-at-h-c-wainwright-28th-annual-global-investment
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Brokerages
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-sana-biotechnology-inc-nasdaq-sana-given-average-rating-of-moderate-buy-by-brokerages-2026-09-15/
Sana Biotechnology op Morgan Stanley conferentie: focus op diabetes
September 15, 2026  |  nl.investing.comhttps://nl.investing.com/news/transcripts/sana-biotechnology-op-morgan-stanley-conferentie-focus-op-diabetes-93CH-914514
Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946244-sana-biotechnology-inc-sana-presents-at-morgan-stanley-24th-annual-global-healthcare
Sana Biotechnology出席富国银行医疗健康大会：两大核心项目即将进入临床阶段
September 10, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3556440
Sana Biotechnology出席花旗2026年生物医药返校峰会：押注糖尿病疗法
September 10, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3561461
Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945241-sana-biotechnology-inc-sana-presents-at-citigroups-biopharma-back-to-school-summit-2026
Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945095-sana-biotechnology-inc-sana-presents-at-wells-fargo-21st-annual-healthcare-conference
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
September 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-sana-biotechnology-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302870954.html
Sana Biotechnology to Present at September 2026 Investor Conferences
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354578/0/en/sana-biotechnology-to-present-at-september-2026-investor-conferences.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

CareDx stock logo

CareDx NASDAQ:CDNA

$65.43 +2.31 (+3.66%)
Closing price 04:00 PM Eastern
Extended Trading
$65.74 +0.31 (+0.47%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Celcuity stock logo

Celcuity NASDAQ:CELC

$63.19 -2.66 (-4.04%)
Closing price 04:00 PM Eastern
Extended Trading
$63.46 +0.27 (+0.43%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$34.26 -1.80 (-4.99%)
Closing price 04:00 PM Eastern
Extended Trading
$34.28 +0.02 (+0.07%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Sana Biotechnology stock logo

Sana Biotechnology NASDAQ:SANA

$2.41 -0.21 (-8.02%)
Closing price 04:00 PM Eastern
Extended Trading
$2.44 +0.02 (+1.04%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas